Mitochondrial Gene Therapy Passes Final U.K. Vote
By Gretchen Vogel,
Science Insider
| 02. 24. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
The United Kingdom’s House of Lords has approved legislation to allow a new type of in vitro fertilization (IVF) that would replace faulty DNA, preventing certain types of genetic diseases. The vote follows the House of Commons approval of the measure on 3 February, making the United Kingdom the first country to explicitly allow the procedure, which would combine DNA from two biological parents and an egg donor.
The technique will be allowed under fairly tight regulation: Researchers who wish to offer the service to couples still must apply for and receive a license from the country’s Human Fertilisation and Embryology Authority.
The technique, called mitochondrial DNA replacement therapy, would allow women who have mutations in the DNA of their mitochondria, the organelles that provide chemical energy for cells, to have genetically related children who don’t carry the mutations. It is controversial, however, because it would modify the DNA of an embryo in a way that could be passed on to future generations.
People who have faulty mitochondria can experience a variety of symptoms, including heart problems...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...